Review

2011 Update on Pancreas Transplantation: Comprehensive Trend Analysis of 25,000 Cases Followed Up Over the Course of Twenty-Four Years at the International Pancreas Transplant Registry (IPTR)

Angelika C. Gruessner

Manuscript submitted April 11, 2011; resubmitted April 19, 2011; accepted May 11, 2011.

Keywords: diabetes, pancreas transplantation, mortality, donor factors, surgical techniques, immunosuppressive protocols, UNOS

Abstract

AIM: This study aimed to analyze the outcome of pancreas and pancreas-kidney transplantations based on the comprehensive follow-up data reported to the International Pancreas Transplant Registry (IPTR). METHODS: As of December 2010, more than 35,000 pancreas transplantations have been reported to the IPTR: more than 24,000 transplantations in the US and more than 12,000 outside the US. Cases with follow-up information until March 2011 were included in the analysis. RESULTS: Pancreas transplantations in diabetic patients were divided into 3 categories: those performed simultaneously with a kidney (SPK) (75%), those given after a previous kidney transplantation (PAK) (18%), and pancreas transplantation alone (PTA) (7%). The total number of pancreas transplantations steadily increased until 2004 but has since declined. The largest decrease was seen in PAK, which decreased by 50% from 2004 through 2010. Comparatively, the number of SPK decreased by 7% during this time. Era analysis of US transplantations between 1987 and 2010 showed changes in recipient and donor characteristics. Recipient age at transplantation increased significantly as well as transplantations in type 2 diabetes patients. The trend over time was towards tighter donor criteria. There was a concentration on younger donors, preferable trauma victims, with short preservation time. Surgical techniques for the drainage of the pancreatic duct changed over time, too. Now enteric drainage is the predominantly used technique in combination with systemic drainage of the venous effluent of the pancreas graft. Immunosuppressive protocols developed towards antibody induction therapy with tacrolimus and MMF as maintenance therapy. The rate of transplantations with steroid avoidance increased over time in all 3 categories. These changes have led to improved patient and graft survival. Patient survival now reaches over 95% at one year post-transplant and over 83% after 5 years. The best graft survival was found in SPK with 86% pancreas and 93% kidney graft function at one year. PAK pancreas graft function reached 80%, and PTA pancreas graft function reached 78% at one year. In all 3 categories, early technical graft loss rates decreased significantly to 8-9%. Likewise, the 1-year immunological graft loss rate also decreased: in SPK, the immunological 1-year graft loss rate was 1.8%, in PAK 3.7%, and in PTA 6.0%. CONCLUSIONS: Patient survival and graft function improved significantly over the course of 24 years of pancreas transplantation in all 3 categories. With further reduction in surgical complications and improvements in immunosuppressive protocols, pancreas transplantation offers excellent outcomes for patients with labile diabetes.

Fulltext: HTML , PDF (521KB)

This article has been cited by other articles:

	The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation Rangel EB Expert Opin Drug Metab Toxicol 2012. Epub
	T cell autoreactivity in the transplant milieu Matthis J, Nepom GT Am J Transplant 2012. 12(7):1674-1681
	Imaging of miscellaneous pancreatic pathology (trauma, transplant, infections, and deposition) Holalkere NS, Soto J Radiol Clin North Am 2012. 50(3):515-528
	Curing diabetes with transplantation? Richter A, Lerner SM, Schröppel B Mt Sinai J Med 2012. 79(2):267-275
	Portal venous versus systemic venous drainage of pancreas grafts: impact on long-term results Bazerbachi F, Selzner M, Marquez MA, Norgate A, Aslani N, McGilvray ID, Schiff J, Cattral MS Am J Transplant 2012. 12(1):226-232
	Pancreas graft thrombosis: causes, prevention, diagnosis, and intervention Farney AC, Rogers J, Stratta RJ Curr Opin Organ Transplant 2012. 17(1):87-92
	Long-term outcome after pancreas transplantation Gruessner AC, Sutherland DE, Gruessner RW Curr Opin Organ Transplant 2012. 17(1):100-105
	Progress in abdominal organ transplantation Kosieradzki M, Lisik W, Rowinski W, Malkowski P Med Sci Monit 2011. 17(12):RA282-RA291
	Cell therapy in type 1 diabetes Gioviale MC, Bellavia M, Damiano G, Buscemi G J Stem Cell Res Ther 2011. S2:4
	Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients Boggi U, Vistoli F, Amorese G, Giannarelli R, Coppelli A, Mariotti R, Rondinini L, Barsotti M, Piaggesi A, Tedeschi A, Signori S, De Lio N, Occhipinti M, Mangione E, Cantarovich D, Del Prato S, Mosca F, Marchetti P Rev Diabet Stud 2011. 8(2):259-267
	The IKEM Pancreas and Islet Transplant Program as Part of Healthcare for Type 1 Diabetes Patients: Retrospective Analysis of Outcome from 1983 to 2010 Girman P, Saudek F Rev Diabet Stud 2011. 8(1):35-43